Inscripta Stock
Inscripta is a gene editing technology company.
Sign up today and learn more about Inscripta Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Inscripta Stock
Inscripta is a gene-editing technology company that puts researchers in control by making it easy for them to get all they need for cutting-edge, forward cell-engineering. These tools include a family of CRISPR enzymes (called MADzymes), custom nucleases for researchers and commercial partners, and a full suite of gene-editing tools (instruments, reagents, and software) that will significantly increase the speed and efficiency of multiplexed, precision gene editing. By removing the barriers to forward cell engineering and gene-editing research, Inscripta will usher in a new era of advances to revolutionize how we feed, fuel, and heal humanity. Inscripta is led by several genomic technology veterans including CEO Kevin Ness, who co-founded QuantaLife and 10x Genomics, and John Stuelpnagel, the chairman of the company's board, who was co-founder and first CEO of Illumina and chairman of 10x Genomics. Inscripta is headquartered in Boulder, Colo.; has offices in Pleasanton, Calif.; and is backed by Venrock, MLS Capital, NanoDimension, Foresite, Paladin Capital Group, and MĂ©rieux DĂ©veloppement.
Investors
NanoDimension
Funding History
April 2016 | $6.0M |
---|---|
February 2017 | $23.1M |
February 2018 | $55.5M |
January 2019 | $50.0M |
November 2019 | $175M |
March 2021 | $150M |
Management
General Counsel
Dianna DeVore
VP Finance
Eric Warnecke
CSO & Founder
Ryan T Gill
VP Product Development
Michael Graige
VP Software
Todd Rubano
VP Biology
Paul Hardenbol
Executive Director of Data Science
Richard Fox
CEO
Kevin Ness
CTO, VP R&D, Co Founder
Tanya Lipscomb
VP Engineering
Don Masquelier
Press
forbes - Jan, 25 2023
Inscripta Is Reimagining What The Synthetic Biology Company Of The Future Will Beendpts - Jan, 20 2023
In bid to advance manufacturing capabilities, Inscripta buys out two biotechsgenomeweb - Jan, 19 2023
Inscripta Acquires Infinome Biosciences, Sestina Bioagfundernews - Jan, 12 2023
Inscripta Acquires Former Illumina Team via Solana Biosciences to Commercialize Gene Editing Toolsbizwest - Dec, 20 2022
Inscripta to close Boulder HQ, triggering âmass layoffâ